138 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants annually; and
the risks described under … minutes from the Type C meeting with the FDA. The Type C meeting minutes indicate that the FDA and the Company are in agreement with a majority
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, Inc. (“Fortress”) controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants … with a majority of the proposed protocol items and are in active discussion about remaining open items. The minutes indicate that the FDA also agrees
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall … Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding
8-K
EX-10.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the board of directors of the Company … or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, and (D
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
; the fact that Fortress Biotech, Inc. controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share
8-K
EX-4.2
vhj6xfpzcy 1655mh99
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.1
5fsudv w2
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-3.1
6yt8ytm2ltw2ewtk
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
1y6yoxsg
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
DEF 14C
mhx1fpl3fvosg2u
18 Mar 24
Information statement
4:59pm
8-K
EX-99.1
tggofgd
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
PRE 14C
pql9xblv24n86ar27f
8 Mar 24
Preliminary information
4:31pm
8-K
v6mvf6mptx
8 Mar 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
0c8w6
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
EX-3.1
ecnfcsn7 5kfc
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm
424B3
6comd
2 Feb 24
Prospectus supplement
12:00am
DEF 14C
wedyg3 x4xe
29 Jan 24
Information statement
8:00am